Non-Small Cell Lung Cancer in China: Discussing Local and Systemic Options

What local and systemic options mean in NSCLC

In non-small cell lung cancer, clinicians often separate two broad groups of treatment. Local options target the cancer where it sits, such as surgery to remove part of a lung, or radiotherapy directed at a specific area. Systemic options travel through the body, such as chemotherapy, targeted therapy or immunotherapy. Many patients are offered a combination, or a sequence, depending on stage, pathology and biomarker results.

The word 'option' does not mean the treatment is suitable for you. Suitability depends on the tumour's type, its molecular features, where it has spread, your lung function, your general health and what treatment you have already had. A China team can only discuss this meaningfully if it can see the reports that establish those facts. Without them, any reply is general rather than case-specific.

A lung lobectomy removes a lung lobe. It is different from removal of an entire lung. That distinction matters when you are asking whether surgery is part of your local options, and it is one reason the operative plan and the pathology report need to be read together.

The records that decide whether a discussion is useful

Before a specialist can comment on local and systemic options, they need the documents that define your cancer. The most important are the pathology report (including the histological type), the staging information, and any biomarker or molecular test results such as EGFR, ALK, ROS1, PD-L1 or others your treating team has ordered. If you have had treatment already, the previous regimen, dates, response and any toxicity matter as much as the original diagnosis.

Imaging is equally important: the CT, PET-CT or MRI reports that show where the disease is now, plus the actual images if they can be shared. A written report alone may not be enough for a surgeon or radiation oncologist to judge whether a local approach is technically possible. If you have had a biopsy or surgery in another country, the pathology slides or blocks may be requested for review, because a second read can change the interpretation.

You do not need to send everything at once. A short summary first, then the key reports, is usually the practical route. The initial enquiry is free and asks for a brief summary, not a complete medical archive.

• Pathology report with histological type and, if available, the original slides or blocks.
• Staging documents: imaging reports and the stage recorded by your treating team.
• Biomarker or molecular test results, with the laboratory and the date.
• Previous cancer therapy: drugs, dates, response and any significant side effects.
• Current imaging reports and, if shareable, the images themselves.
• A short list of your main questions, in your own words.

Why a preliminary reply is not a treatment plan

When you send records to a hospital or coordination service, the first reply is often an acknowledgement that the file has been received and a request for missing items. That is not a clinical decision. A records-based opinion can explain how a team might approach a case and what further information it needs, but it cannot confirm that you will be accepted for treatment, that a particular drug is available, or that a procedure will go ahead.

This matters because patients sometimes read a warm preliminary reply as a green light and start making travel plans. A more reliable sequence is: records reviewed, missing items identified, a specialist appointment or records-based opinion arranged, and only then a discussion about whether travelling to China is worthwhile for your situation. The hospital, not the coordination service, decides suitability.

If your symptoms are worsening, or you have new breathlessness, pain or bleeding, that needs urgent local assessment. An overseas enquiry should not delay care where you are.

Questions to ask about local options

Local options in NSCLC include surgery, radiotherapy and, in some situations, ablative techniques. Whether any of these is relevant depends on the stage, the location of the tumour and your lung function. A thoracic surgeon and a radiation oncologist may reach different views, which is one reason a multidisciplinary discussion can be useful for complex cases.

When you speak with a clinician, ask what specifically makes you a candidate or not for a local approach. Ask whether the decision depends on tests you have not yet had, and whether those tests can be done locally before you travel. Ask what the proposed operation would involve, what part of the lung would be removed, and what the alternatives are if surgery is not advised.

For radiotherapy, ask about the technique, the number of sessions and the planning scans required. These are clinical questions for the treating team. The answers will differ between patients, and no article can substitute for that assessment.

• Which local option is being considered for me, and why?
• What tests or scans are still needed before that decision can be made?
• If surgery is proposed, what exactly would be removed, and what is the expected effect on my breathing?
• If radiotherapy is proposed, what technique and schedule are planned?
• What are the alternatives if the local option is not suitable?

Questions to ask about systemic options

Systemic treatment for NSCLC is increasingly guided by biomarker results. If a targetable mutation is found, a targeted therapy may be discussed. If PD-L1 expression is high, immunotherapy may be part of the plan. Chemotherapy remains relevant in many situations, sometimes combined with other drugs. The right sequence depends on the specific tumour and on what you have already received.

Ask the treating team which biomarker results are available and which are missing. Ask whether the recommended systemic option is approved in China, whether it is available at the hospital you are considering, and what the monitoring plan would be. Ask how the team would judge whether the treatment is working, and what would prompt a change.

Availability and access are hospital-specific and can change. A clinician or the hospital's international office is the right source for whether a particular medicine can be prescribed for you there. A coordination service can help arrange appointments and interpretation, but it does not prescribe, dispense or decide suitability.

• Which biomarker results do you have, and which are still needed?
• What systemic option are you proposing for me, and what is the evidence for it in my situation?
• Is that treatment available at this hospital, and what would the monitoring involve?
• What would you do if the first systemic treatment stops working?
• How would you manage side effects, and who would I contact between visits?

How to compare a China discussion with your current care

Many patients seek a China opinion not because they have been told nothing can be done, but because they want to know whether a different combination of local and systemic treatment is worth considering. That is a reasonable question, and it is best asked with your current records in hand. Ask your present team what they would want to know before changing course, and ask the China team the same question.

If you request a records-based opinion, ask what the fee covers and what it does not. Ask whether a specialist will review the actual images and pathology, or only the reports. Ask how the opinion will be delivered and in what language. These are practical points that affect how useful the reply will be.

For some patients, a proxy consultation or a multidisciplinary review is a sensible way to get a structured opinion without travelling first. Neither is mandatory. An initial enquiry does not require buying a proxy consultation, and the hospital decides whether to accept you for treatment.

Related treatment reference

Next step

Start with a short summary of your situation: the diagnosis or suspected diagnosis, the date, the pathology and biomarker results you have, the treatment you have already received, and the one or two questions you most want answered. You can send this through the enquiry form, by email or by WhatsApp. The initial review is free and is not a diagnosis or a promise of acceptance. If you decide to go further, the team can explain how to share records securely and what a specialist appointment or records-based opinion would involve.

Keep your local treating team informed. A China discussion is most useful when it adds to your existing care, not when it replaces urgent assessment where you are.